Nanozyme and Infrared Light: A New Breakthrough in Treating Brain Tumors

Researchers at the Swiss Federal Laboratories for Materials Science and Technology, known as Empa and the St. Gallen-based company Hoch Health have developed a nanozyme designed to treat brain tumors through the use of infrared light.

The development focuses on the use of nanomaterials that mimic the activity of natural enzymes. These nanozymes are engineered to remain inactive until they are triggered by a specific external stimulus, in this case, near-infrared light, which allows for a more localized application of the treatment within the brain.

The Mechanism of Light-Activated Nanozymes

Nanozymes are nanoparticles that possess enzyme-like catalytic properties. Unlike traditional protein-based enzymes, which can be unstable or trigger immune responses, these synthetic alternatives are often more robust and easier to mass-produce.

According to reporting from Admin.ch and Sardona24, the specific nanozyme developed by Empa and Hoch Health is activated by infrared light. When the light penetrates the tissue and hits the nanozyme, it triggers a chemical reaction intended to destroy tumor cells.

This approach aims to address one of the primary challenges in neuro-oncology: the ability to target malignant cells without damaging the surrounding healthy brain tissue. Because the nanozyme only becomes active where the infrared light is focused, the potential for collateral damage to non-cancerous regions of the brain is reduced.

Overcoming Barriers in Brain Tumor Treatment

Treating brain tumors is complicated by the blood-brain barrier, a highly selective semipermeable border that prevents many systemic chemotherapy drugs from reaching the brain. This often necessitates invasive surgeries or high-dose radiation, both of which carry significant risks of neurological impairment.

The use of near-infrared light is a strategic choice in this research. Near-infrared wavelengths can penetrate deeper into biological tissues than visible light, making them more suitable for reaching tumors located beneath the skull or within deeper brain structures.

By combining the precision of light-based activation with the catalytic power of nanozymes, the collaboration between Empa and Hoch Health seeks to create a therapeutic window that is both narrow and potent, focusing the destructive force of the medicine exclusively on the tumor site.

Collaboration and Regional Development

The project represents a partnership between academic research and industrial application. Empa provides the materials science expertise necessary to engineer the nanoparticles, while Hoch Health, based in St. Gallen, focuses on the medical application and development of the therapy.

This regional collaboration in Switzerland highlights a trend toward integrating nanotechnology into personalized medicine. The goal is to move away from broad-spectrum treatments toward therapies that can be “switched on” and “switched off” based on the precise location of the pathology.

Current Status and Future Outlook

While the development of these light-activated nanozymes shows promise in laboratory settings, the transition to clinical use involves several hurdles. Researchers must continue to verify the safety of the nanoparticles, ensuring they are fully biodegradable or can be safely cleared from the brain after the treatment is complete.

Further studies are required to determine the optimal dosage of nanozymes and the precise parameters of the infrared light needed to maximize tumor destruction while minimizing heat-related damage to healthy tissue.

The development marks a significant step in the field of nanomedicine, suggesting a future where brain tumors could be managed with less invasive, light-triggered interventions rather than relying solely on traditional surgical resection or systemic toxins.